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Both comments suggest adjuvant retroperitoneal
lymph node dissection for patients with stage I dis-
ease and presence of pathological risk factors. This
conclusion is based on the experience in several high
volume centers and is supported by our findings. Our
review indicated that men with visible metastatic
Leydig cell tumors have a very poor prognosis and
that the retroperitoneum represents the primary
landing zone in two-thirds of oligometastatic cases.
Therefore, RPLND is thought to cure micro-
metastatic disease in the retroperitoneum and the
indication is heavily dependent on the pathology
report, requiring a dedicated and experience uropa-
thologist. Furthermore, RPLND should only be per-
formed at centers with adequate expertise regardless
of whether minimally invasive or open. Overall
Leydig cell tumors represent a rare disease with
potentially fatal outcomes suggesting centralized
care. Our review resulted in new insights from pub-
lished series but still leaves several questions unan-
swered. Therefore, we encourage centers to
contribute data of patients with rare testis cancer
histologies to our OATH registry (http://bit.ly/OATH-
registry).
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